Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 8/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593434 | 0.88 | GRM2 (0.38) | EGLN2EGLN1GRM2 | |
| SCHEMBL3896068 | 0.87 | EGLN2 (0.41) | EGLN2EGLN1MAOAMCHR1 | |
| SCHEMBL13850908 | 0.86 | EGLN2 (0.45) | EGLN2EGLN1 | |
| SCHEMBL3895015 | 0.85 | EGLN2 (0.40) | EGLN2EGLN1MAOAMCHR1 | |
| SCHEMBL3899093 | 0.84 | GRM2 (0.40) | GRM2 | |
| SCHEMBL3890871 | 0.84 | EGLN2 (0.38) | EGLN2EGLN1GRM2MAOA | |
| SCHEMBL3963691 | 0.83 | KDM4E (0.36) | EGLN2EGLN1GRM2 | |
| SCHEMBL3898382 | 0.83 | GRIN2B (0.38) | EGLN2EGLN1GRM2MAOAMCHR1 | |
| SCHEMBL3891640 | 0.83 | EGLN2 (0.38) | EGLN2EGLN1 | |
| SCHEMBL13850960 | 0.82 | LTA4H (0.35) | EGLN2EGLN1GRM2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-20060247212-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2006-11-02 | — | — | US | disclosed |
| US-20060128669-A1 | Heterocyclic compounds having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1541558-A1 | HETEROCYCLIC COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | CYP3A7, CDK7, CYP2A7 | EGLN2 3504/4885EGLN1 3314/4885GRM2 4122/4885 |
| US-20060247212-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | CYP3A7, CDK7, CYP2A7 | EGLN2 3496/4885EGLN1 3279/4885GRM2 4144/4885 |
| US-20060128669-A1 | Heterocyclic compounds having inhibitory activity against hiv integrase | CYP3A7, CDK7, CYP2A7 | EGLN2 3504/4885EGLN1 3314/4885GRM2 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.